Magnitude Biosciences, a specialist contract research organisation (CRO) and Durham University spinout, has secured £1.3 million ($1.7 million) in funding to accelerate the commercialisation of VivoScan, its proprietary in vivo high-throughput screening (HTS) platform.  

VivoScan is unique in providing HTS for drug discovery in a whole organism. Unlike conventional HTS, which typically measures a limited number of molecular or cellular endpoints, VivoScan captures rich biological responses across a living organism.  

The VivoScan platform uses hundreds of nematode worms, C. elegans, as a biological model to evaluate potential therapies. By combining worms with advanced imaging, machine learning, agentic AI, automation and robotics, Magnitude Biosciences says it can generate highly detailed whole-organism data in weeks rather than years.  

 Screening a whole organism  

Magnitude’s solution has the potential to transform how new drug therapies are discovered and developed. By rapidly screening thousands of compounds while providing detailed biological insights from a whole-organism system, the company is helping bridge the gap between laboratory research and clinical development, potentially accelerating drugs designed to extend the healthspan of our ageing population. 

Dr Fozia Saleem, CEO, Magnitude Biosciences, says: “Our ambition is to become the first company to provide a platform to screen millions of compounds in a whole organism. This investment in VivoScan gives us the opportunity to turn that ambition into reality and fundamentally change the scale and speed at which drug discovery can be done. 

“We are building a platform that can move beyond simply screening more compounds. VivoScan generates rich, whole organism biological data that can help researchers understand how potential therapies affect health, ageing and disease. By making data generation faster and more cost effective, we will be able to help pharmaceutical and biotechnology companies identify better drug candidates earlier and ultimately accelerate the development of new treatments.” 

Northstar Ventures led the round through the North East Spinout Inspire Fund, the North East Innovation Fund and the Northstar EIS Growth Fund, alongside investment from Maven’s regional funds and new angel investors, with the funding also unlocking a further £217,000 Innovate UK Investor Partnership grant.